ECHO IQ Aktie

 

Echo IQ studies next steps after FDA finds EchoSolv HF 510(k) not substantially equivalent; will engage FDA directly while EchoSolv AS stays cleared....

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL ECHO IQ LTD. PL4 AU0000195430 BAW/UFN...

Instrument ID [24491891] (PL4 - AU0000195430) suspended...

Echo IQ lands exclusive Advara data licence, unlocking up to 1 million de-identified echocardiograms to power its EchoSolv cardiovascular AI platform....

FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN ECHO IQ LTD. PL4 AU0000195430 AB/FROM ONWARDS 01.07.2026 08:03 CET...

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL ECHO IQ LTD. PL4 AU0000195430 BAW/UFN...

Instrument ID [24491891] (PL4 - AU0000195430) suspended...

Echo IQ and Pro Medicus announce up to $20m investment to market EchoSolv HF AI cardiac platform in the US; reseller deal to accelerate adoption....

Pro Medicus has signed a binding agreement with Echo IQ to boost its AI-driven cardiology solutions and expand commercial opportunities. The post Pro Medicus signs Echo IQ deal to boost AI cardiology offering appeared first on The Motley Fool Australia....

SYDNEY, June 24, 2026 (GLOBE NEWSWIRE) -- AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) ("Echo IQ" or "the Company") today announced two key appointments to its executive leadership team and broader clinical advisory network to support the next phase of commercial growth for its EchoSolv platform, expand its presence within the U.S. healthcare market and advance regulatory initiatives with the U.S. FDA. Matthew Dodds has been appointed Chief Financial Officer, effective 24 June 2026, and Dr. Vinod Thourani, internationally recognised as one of the foremost authorities in structural heart disease, heart valve therapies and cardiovascular surgery, has been appointed Clinical Advisor....

Echo IQ's AI platform to be evaluated in collaboration with Mayo Clinic for assessing cardiac risk in patients receiving cancer therapy Echo IQ's AI platform to be evaluated in collaboration with Mayo Clinic for assessing cardiac risk in patients receiving cancer therapy...

Echo IQ (ASX: EIQ) has secured a research collaboration with Mayo Clinic…...

Echo IQ teams with Mayo Clinic Arizona to test AI-driven cardiac risk scores from echocardiography in cancer patients; results expected 2027....

SYDNEY, April 30, 2026 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company”) (ASX: EIQ) is pleased to advise it has deployed its AI-based decision support software for the assessment of severe aortic stenosis, EchoSolv™ AS, with Mount Sinai Health System in New York, USA....

Echo IQ expands Mayo Clinic distribution for EchoSolv HF; FDA clearance pending, auto-renew 3 years, unlocking Mayo Clinic Platform (MCP) network....

SYDNEY, Nov. 24, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology Company Echo IQ Limited (ASX: EIQ) (“Echo IQ” or “the Company”) is pleased to advise that it has completed its clinical validation for its heart failure clinical decision support software (“EchoSolv HF”) in collaboration with the Mayo Clinic Platform (“MCP”), a division of the Mayo Clinic, a top ranked US hospital. The MCP Validate program is a unique in-market AI evaluation program which generates an independent and objective report on accuracy, efficacy and susceptibility to bias for AI-based decision software (refer ASX Announcement 1 July 2025)....

SYDNEY, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ), today announced that Dustin Haines, Chief Executive Officer, will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 2, 2025, at 12:50 p.m. Eastern Time....

Perth-based medical technology company Echo IQ (ASX: EIQ) has reported strong operational momentum from its EchoSolv AS platform in the US market, with a 153% increase in echocardiograms over the three months to September. The performance has come about through extensive engagement with US hospital groups, which have integrated the technology into their operations, resulting in the […] The post Echo IQ Reports Strong US Performance of EchoSolv AS Platform Ahead of Regulatory Clearance appeared first on Small Caps....